Qiantang New District 10 health care enterprises shortlisted for the "quasi-unicorn" list, 90% gathered in Hangzhou Medical Port

"
Pharmaceutical Network Industry Dynamic" In the field of entrepreneurship and innovation, "unicorn" is an eye-catching vocabulary, the number of unicorns is also a measure of urban entrepreneurship innovation environment and future development potential of an important indicatorrecently, Hangzhou released the "2020 Hangzhou Unicorns and Quasi-Unicorn Enterpriselist", 31 "unicorn" enterprises and 142 "quasi-unicorn" enterprises on the list, the total valuation of all enterprises more than 310 billion U.SdollarsThese enterprises are mainly concentrated in big data, artificial intelligence, e-commerce, health care, enterprise services, culture, entertainment and sports, education and other fieldsAmong them, Qiantang New District has 13 quasi-unicorn enterprises shortlisted, medical and health enterprises up to 10, the new area of the biopharmaceutical industry was re-glazedthe 10 medical health quasi-unicorn enterprises, including Aotai Bio, Polyjus, Mingfeng Medical, Jinzhen Biology, Zhuo Jian Technology, First Ford Bio, Soyuan Bio, Gao Cheng Biology and so onAmong them, there are 9 enterprises from Hangzhou Pharmaceutical Port, only the early sieve this one is located in the small town of DachengIn recent years, with the formation and perfection of innovative ecology in the field of life science and technology in China, start-ups with unique technologies have emerged, and more and more regions have paid more attention to and vigorously developed the biopharmaceutical industryIn May 2018, Hangzhou Medical Port was awarded the title of "Hangzhou Medical Port" after nearly 3 years of development as one of the first Hangzhou-level specialty townsSince then, Hangzhou Pharmaceutical Port, as the core area of the development of the biopharmaceutical industry in Hangzhou, has gradually constructed a full-chain biopharmaceutical innovation and entrepreneurial ecology featuring "six chains", with the output value accounting for nearly 50% of Hangzhouat present, Hangzhou Pharmaceutical Port's industrial chain, from laboratory research, preclinical research, clinical trials to registration approval, drug production, to the market sales of the full coverageThe unique supporting environment, prompting these focused on technology research and development-oriented pharmaceutical departments to create "quasi-unicorns" pile togetherin January this year, the Hangzhou-based pharmaceutical port of Stranson Group completed a $100 million financing, including Lilly Asia fund Temasek, GaoYu Capital and other well-known investment institutionsToday, Transsolar Group has the ability to integrate the entire process of drug discovery, process development, clinical development and production, successfully partnering with Lilly Pharmaceuticals to obtain a Greater China license for its entire bone disease innovative biopharmaceutical product line, including Blosozumab, which has completed Phase 2 clinical trials on June 28 this year, the same from Hangzhou Pharmaceutical Port, Yingchuan Bio announced that it has completed a total of 115 million yuan b round of financing Focusing on the development of high-efficiency, low-cost gene capture technology, Lianchuan Bio will continue to increase research and development of key technologies in the gene testing industry, in addition, China's precision medical enterprise Suyuan Bio june 29 news, completed the 590 million yuan scale of C-round financing This round of financing is led by CICC Qide Innovative Biopharmaceutical Equity Investment Fund The oversubscription of this financing will provide ample funding for the next phase of the development of Soyuan Bio and further expand the new drug pipeline to build the foundation it is understood that in Hangzhou Pharmaceutical Port's industrial chain, has gathered more than 1000 biotechnology enterprises, covering biopharmaceuticals, medical devices, biomedical engineering, medical big data and other core areas, Pfizer, Mercadong and other global TOP10 pharmaceutical companies have 7 settled here in the field of innovation transformation and ecological development, Hangzhou Pharmaceutical Port has built 11 innovative service platforms with famous universities around the world, Zhejiang University Hospital Innovation and Transformation Center, Zhejiang University Hospital Hangzhou Pharmaceutical Port Clinical Trial Center, Hangzhou Pharmaceutical Port Biological Drug Research and Development Public Service Platform, Zhejiang Medical Devices The public service platforms such as the inspection institute and the well-known third-party biomedical science and technology service institutions at home and abroad have landed, building from laboratory research, pre-clinical research, clinical trials to registration approval, drug production, until the full support chain of marketing and sales, can be targeted for early innovation and start-up projects to complement the short board , Hangzhou Pharmaceutical Port has also established a "pyramid" talent system of "leading, research and development and practicality", while the park plays a 5 billion yuan industrial mother fund energy efficiency, the United Nations domestic and foreign leading pharmaceutical fund formed a financial chain, continue to inject vitality into innovative entrepreneurship projects At present, the financial chain of the park has completed 22 project stakes, the actual investment amount of more than 700 million yuan.